A phase III trial showed that the combination of elesclomol and paclitaxel did not benefit most people with melanoma. Elesclomol is an experimental drug that can kill cancer cells and paclitaxel is a chemotherapy drug. The trial included 651 people; the combination treatment was stopped early when it became clear that most of those treated with paclitaxel alone survived longer. Most of these people also had high levels of an enzyme called lactose dehydrogenase (LDH). Conversely, elesclomol did increase survival in people with normal levels of this enzyme, suggesting that LDH levels could be used to predict who would benefit from this combination treatment.